Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes-EV-based Therapeutics Summit

Exosomes-EV-based Therapeutics Summit Agenda

Co-Located Conference Agendas

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 | Exosomes-EV-based Therapeutics Summit | 

Print Agenda

Friday, 1 November 2019


Dominique PV de KleijnConference Chair

Chairman's Introduction to Exosomes/EV-based Therapeutics Field
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands


Sai Kiang LimKeynote Presentation

Innate and Adaptive Immune Modulation by MSC Small Extracellular Vesicles
Sai Kiang Lim, Research Director, Institute of Medical Biology, A*STAR, Singapore

Mesenchymal stromal cell (MSC) is the most clinically tested cell type for regenerative medicine.  It has significant immunomodulatory potency as evidenced by recent market approval for use in GVHD and Crohn’s disease.  It exerts at least part of this potency through secreted small extracellular vesicles of 50 to 200 nm diameter.  We have previously shown that MSC-sEVs have both innate and adaptive immunomodulatory activities.  They activated TLR4 in monocytes to elicit an anti-inflammatory cytokine secretion profile that was different from the pro-inflammatory profile elicited by LPS-mediated TLR4 activation.  The TLR4 activation by MSC-sEVs was neutralized by a blocking antibody against EDA-containing fibronectin, a TLR4 ligand that is present in MSC-sEV preparations.  MSC-sEVs also induced mouse CD4+CD25+ T cells or CD4+CD25+Foxp3+ Tregs from CD4+ T cells activated by allogeneic APC-enriched CD11C+ cells but not those activated by anti-CD3/CD28 mAbs. This induction was MSC-sEV and APC dose–dependent.


Christine HappelKeynote Presentation

The NIH Extracellular RNA Communication Consortium: Advancing Knowledge and Technologies for Extracellular RNA Research
Christine Happel, Scientific Program Manager, National Center for Advancing Translational Sciences (NCATS), United States of America

The discovery that secreted RNA (exRNA) is transported between cells through extracellular vesicles (EVs) suggested that exRNAs plays an important role in intercellular communication. Moreover, exRNAs also have utility as biomarkers of disease and as therapeutic agents. However, many gaps in knowledge and technical challenges in EVs and exRNA biology, such as mechanisms of EV biogenesis and uptake, exRNA cargo selection, and exRNA function. Moreover, efficient and reproducible methods for isolation and analysis of EVs and exRNAs were not available. The NIH Common Fund-supported exRNA Communication Consortium (ERCC) was launched in 2013 to address the major scientific challenges in this field. Participating laboratories from the 30 funded ERCC projects have worked individually and collaboratively to work toward these goals. This presentation will highlight the ERCC tools and resources developed, and scientific highlights particularly in biomarker discovery and therapeutic development of EV-based exRNA.


Networking Lunch


Exosome-based Delivery of Therapeutic Proteins: Principles and Applications
Chulhee Choi, Professor and Chair, BioMedical Imaging Center, Korea Advanced Institute of Science and Technology (KAIST), President, ILIAS Biologics Incorporated, Korea South

Our group has recently developed an opto-genetically engineered exosome system, named ‘exosomes for protein loading via optically reversible protein–protein interaction” (EXPLOR) that can deliver soluble proteins into the cytosol of target cells via controlled, reversible protein–protein interactions (PPI). By integrating a reversible PPI module controlled by specific wavelength of light with the endogenous process of exosome biogenesis, cargo proteins of our interest can be loaded into the exosomes. Engineered exosomes were shown to significantly increase intracellular levels of cargo proteins and their function in the recipient cells in both a time- and dose-dependent manner. In this presentation, I will introduce the basic principles of EXPLOR technology and follow-up studies for therapeutic applications focusing on novel anti-inflammatory exosomes in various disease models.


LonzaExosome, The Next Small Thing: A Winning Strategy to Lead its Manufacturing and Characterization
Behzad Mahdavi, Vice President of Strategic Innovation & Alliances, Lonza

  • Importance of Exosomes in Precision Medicine and Targeted Delivery
  • How expertise and assets in cell manufacturing are essential for Exosome manufacturing  
  • Leverage the exosome-based liquid biopsy, characterization and profiling in therapeutic development manufacturing
  • Cell Therapy Manufacturing + Exosomes Based Liquid Biopsy = A winning combination to lead Exosomes Manufacturing


An Exosome-based Drug Delivery Platform Derived From an Immortalized Human Neural Stem Cell (hNSC) Line
Randolph Corteling, Head of Research, ReNeuron Ltd., United Kingdom

To ensure the scale required for clinical research and commercialisation producer cell immortalisation and clonal isolation is a practical strategy to produce consistent, functionally bioactive exosomes for use as therapeutic agents. Immortalisation ensures production stability and reduces the need for equivalence testing.

CTX0E03 is a conditionally immortalised human neural stem cell line that has been manufactured to clinical-grade (GMP) standards, using a 3-tier banking strategy and is currently in Phase IIb clinical evaluation for disability after stroke. Using the conditioned media produced during GMP manufacture, we have shown that CTX0E03 is an abundant producer of exosomes that can be readily isolated and purified at scale. The CTX cell line can also be rapidly and efficiently modified to direct the expression of a variety of cargoes within the secreted EV population, whilst maintaining the key immortalised stem cell characteristics of the parental cell line.  The natural tissue tropism of CTX-derived exosomes can then be exploited to deliver loaded cargoes to target cells.


Mesenchymal Stem Cell-derived Extracellular Vesicles: A Potential New Tool in Regenerative Medicine
Bernd Giebel, Group Leader, Institute for Transfusion Medicine, University Hospital Duisburg-Essen, Germany

Human mesenchymal stem/stromal cells (MSCs) represent a promising tool in regenerative medicine. Up to now, more than 1000 NIH-registered clinical trials investigated their immunomodulatory and pro-regenerative therapeutic potential in various diseases, including graft-versus-host disease (GvHD) and ischemic stroke. Despite controversial reports regarding the efficacy of MSC-treatments, MSCs seem to exert their beneficial effects rather in a paracrine manner than by cell replacement. In this context, extracellular vesicles (EVs), such as exosomes and microvesicles, are discussed to execute the MSCs’ therapeutic effects. Indeed, we observed beneficial therapeutic impacts of MSC-EVs in a patient, who suffered from steroid-refractory acute GvHD. Furthermore, beneficial effects were observed in animal models for several different diseases.

According to controversial reports in the MSC field, especially since a phase III clinical trial failed to show clinical efficacy in MSC treated GvHD patients, we have started to compare immunomodulatory effects of independent MSC-EV preparations. Indeed, in our in vitro assays independent MSC-EV fractions reveal different immunomodulatory capabilities. To unravel the basis for these differences we are currently using several methods to dissect the heterogeneity between and within given MSC-EV samples.


Chantal BoulangerKeynote Presentation

Extracellular Vesicles and Coronary Artery Diseases
Chantal Boulanger, Research Director, Paris Cardiovascular Research Center, France

My group's current research interests focus on the role of extracellular vesicles in cardiovascular diseases. We investigate their role as mediators of cell-cell communication in the vessel wall as well as their potential as biomarkers of cardiovascular diseases. This brings us to investigate the regulation of extracellular vesicle composition, including non coding-RNA packaging, their biodistribution and how the resulting paracrine effects might affect the development of cardiovascular diseases.


First-In-Human Application of Umbilical Cord MSC-Derived EVs for the Prevention of Cochlear Implant Surgery-Related Injury
Mario Gimona, Head of Manufacturing, GMP Unit, Paracelsus Medical University Salzburg, Austria

Cochlear implantation (CI) can restore hearing perception by bypassing the auditory hair cells (HC) and directly stimulating the spiral ganglion neurons (SGN). Insertion of an electrode array into the cochlea is associated with robust early and chronic inflammatory responses that promote intra-cochlear fibrosis and loss of HC and SGN. Conservation of residual hearing and prevention of fibrous tissue deposition around the electrode are thus major challenges in CI surgery. We have manufactured GMP-compliant umbilical cord (UC)-MSC- derived extracellular vesicles (EVs) and subjected such preparations to a series of in vivo and in vitro assays. Animal studies included both systemic and local injection for the improvement of seemingly unrelated indications such as critical size bone defects, partial tendon rupture and spinal cord injury in a rat contusion-model. In all cases EV application resulted in a significant modulation of immune reaction, overall reduced inflammation and scar reduction as evidenced by a reduction in ECM deposition. In an in vitro spiral ganglion neuron protection assay UC-MSC-EVs outperformed the current best-in-class soluble neuroprotective factor, BDNF. In vivo application of EVs in mice challenged by noise trauma resulted in significant protection of hearing when compared to untreated controls. Reduction of impedance as a measure for current resistance and fibrotic tissue formation around the electrode array were observed in a model of implantation trauma in guinea pigs implanted with an electrode array. After careful consideration of the medical history of a patient requiring CI surgery an experimental healing attempt was performed and the patient received a single intra-cochlear injection of 5 x 109 EVs (total) prior to electrode insertion. The application was tolerated well, no adverse reactions were recorded and robust auditory sensation was detected 6 weeks post surgery. Based on these initial safety data on the local application of EVs in the inner ear, a phase 1/2a clinical trial is currently in preparation to further evaluate the neuroprotective, immunomodulatory and anti-fibrotic potential of UC-MSC-EVs.

Funding:  Project “ Exothera” IT-AT 1036 (EU), Project “ExtraNeu” (Land Salzburg)


Round-Table Discussion on the Opportunities and Industry Trends in the Exosome/EV-Delivery and Therapeutics Space with Coffee


Close of Summit

Add to Calendar ▼2019-11-01 00:00:002019-11-01 00:00:00Europe/LondonExosomes-EV-based Therapeutics SummitExosomes-EV-based Therapeutics Summit in Rotterdam, The NetherlandsRotterdam, The